Puma Biotechnology | PBYI - Ebitda


Puma Biotechnology reported $729K in EBITDA for its fiscal quarter ending in June of 2024.





Ebitda Change Date
Agios Pharmaceuticals USD -115.49M 10.3M Sep/2025
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
Amgen USD 5.14B 775M Dec/2025
Biogen USD 573.2M 253.7M Dec/2025
BioMarin Pharmaceutical USD -24.17M 18.91M Dec/2025
Daiichi Sankyo JPY 101.6B 22.81B Mar/2025
Esperion Therapeutics USD -27.51M 9.5M Sep/2023
Exelixis USD 248.93M 28.02M Sep/2025
Gilead Sciences USD 4.03B 628M Sep/2025
Glaxosmithkline GBP 4.75B 1.52B Sep/2025
Incyte USD 414.5M 92.42M Dec/2025
MacroGenics USD 21.95M 55.39M Sep/2025
Moderna USD -790M 582M Dec/2025
Novartis USD 5.88B 290M Sep/2025
Pfizer USD 6.08B 351M Sep/2025
PTC Therapeutics USD 20.63M 53.74M Sep/2025
Puma Biotechnology USD 729K 11.36M Jun/2024
Regeneron Pharmaceuticals USD 1.92B 261.9M Sep/2025
Roche Holding CHF 12.68B 2.36B Jun/2024
Sarepta Therapeutics USD -168.03M 294.45M Sep/2025
Takeda JPY 448.13B 173.98B Dec/2025
TG Therapeutics USD 32.69M 5M Sep/2025
Ultragenyx Pharmaceutical USD -156.79M 65.44M Sep/2025
Vanda Pharmaceuticals USD -8.31M 2.37M Dec/2024
Vertex Pharmaceuticals USD 1.44B 100.4M Sep/2025